Karuna Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -0.11%148.370.7%$877.32m
BMYBristol-Myers Squibb Co. -4.05%64.161.0%$804.09m
PFEPfizer Inc. -2.16%39.830.9%$667.18m
MRKMerck & Co., Inc. -2.93%85.970.7%$647.43m
ABBVAbbVie, Inc. -2.01%83.562.3%$617.98m
LLYEli Lilly & Co. -1.55%139.021.1%$425.04m
NVSNovartis AG -1.11%93.870.2%$145.91m
GSKGlaxoSmithKline Plc -1.22%47.240.2%$112.00m
APLSApellis Pharmaceuticals, Inc. -2.34%41.300.0%$110.32m
AZNAstraZeneca Plc -1.83%49.281.2%$101.75m
KRTXKaruna Therapeutics, Inc. 0.00%99.750.0%$73.45m
NVONovo Nordisk A/S -0.81%61.090.1%$72.43m
SNYSanofi -1.75%48.730.2%$63.37m
RETAReata Pharmaceuticals, Inc. -6.45%193.493.5%$59.40m
ENDPEndo International Plc -10.24%5.928.8%$43.86m

Company Profile

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.